- Home
- VIR vs OPRA Comparison
VIR vs OPRA Comparison
Compare VIR & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIR | OPRA |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | Norway |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VIR | OPRA |
|---|---|---|
| Price | $10.57 | $17.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $21.00 | ★ $26.29 |
| AVG Volume (30 Days) | ★ 1.8M | 266.4K |
| Earning Date | 11-04-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | $257.66 | $20.36 |
| Revenue Next Year | N/A | $15.27 |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.82 | $11.71 |
| 52 Week High | $12.00 | $20.78 |
Technical Indicators
Market Signals| Indicator | VIR | OPRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 44.03 |
| Support Level | $10.00 | $17.02 |
| Resistance Level | $11.83 | $18.02 |
| Average True Range (ATR) | 0.62 | 0.54 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 30.62 | 44.13 |
Price Performance
Historical ComparisonAbout VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
About OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.